BRAF and cancer: Kinase inhibitors have shown great potential as a TNBC regimen due to their activity as antitumor and antiangiogenic therapies by targeting genes and pathways that play a role in cancer development and proliferation, like targeting EGFR, RON, MET, mTOR, BRAF, MEK, Src, and Bcr/Abl [120,121,122,123,124,125].